Skip to main content

Advertisement

Table 4 Absolute mean changes in the development index of the MP-R scale at week 24

From: A randomized placebo controlled clinical trial to evaluate the efficacy and safety of minocycline in patients with Angelman syndrome (A-MANECE study)

Age equivalents (months)   Group A (Placebo-Minocycline) (N = 11) Group B1 (Minocycline-Placebo) (N = 11) Group B2 (Minocycline- Minocycline) (N = 10) p value
Primary endpoint: Absolute mean changes in the DI (age equivalent in months) of the MP-R Scale
Development index Baseline 12·55 (6·53) 13·09 (6·31) 10·80 (6·33) 0·699
Week 24 14·80 (6·17) 13·00 (7·89) 7·80 (5·63) 0·689
Absolute mean change 1·30 (4·32) −0·09 (3·93) −3·00 (5·90) 0·139
Secondary analysis: Development index after 8-week wash-out period
Development index Absolute mean change −0·80 (3·39) −1·00 (3·94) −4·20 (8·79) 0·365
Age equivalents (months)   After 8 weeks from the suspension of Minocycline (N = 21) After 16 weeks from the suspension of Minocycline (N = 11)   Absolute mean differences, 95% CI, p value
Development index Absolute mean change −0·94 (3·67) −2·27 (4·12)   −1·32· 95% CI (− 1·65–4·30)